Why Are VYNE Therapeutics Shares Trading Higher Today?

  • VYNE Therapeutics Inc VYNE announced new preclinical data showing the effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis (IPF).
  • VYN201 at 0.5 mg/ml and 1 mg/ml demonstrated statistically significant reductions in Ashcroft scores (a measurement of lung fibrosis) and levels of the tissue fibrosis biomarker compared to the placebo control group.
  • Also Read: VYNE Therapeutics Touts Encouraging Pharmacokinetic, Hematology Data From Potential Candidate For Skin Disorder.
  • Mean control-adjusted lung fibrosis scores for VYN201 1 mg/ml were 65.8% lower than the placebo control group.
  • VYN201 demonstrated a dose-dependent improvement in blood oxygen saturation.
  • The mean blood oxygen saturation for the VYN201 1 mg/ml group was 92.4%, an 8.8% improvement compared to the placebo group (83.6%). The mean blood oxygen saturation for the untreated and unstimulated control group was 95.2%.
  • Treatment with VYN201 1 mg/ml resulted in a 51.8% mean improvement in functional lung volume compared to animals receiving placebo treatment.
  • Price Action: VYNE shares are up 48.2% at $4.64 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!